Overview
PEAK Surgical’s mission is to provide physicians with surgical tools that have the precision of a scalpel and the bleeding control of traditional electrosurgery without the extensive collateral damage.
Preclinical Study Results
Results from a preclinical study evaluating the PEAK pulsed plasma technology in the healing of surgical incisions compared with standard electrosurgery and scalpels were presented in an oral presentation at the American College of Surgeons 93rd Annual Clinical Congress in October 2007. The PEAK PlasmaBlade, which uses pulsed plasma energy to create surgical incisions, was shown to efficiently cut tissue with minimal bleeding, tissue injury and scarring.
Among the key findings:
- The PEAK PlasmaBlade reduced bleeding by 60 percent compared with a scalpel, while providing the same positive wound healing profile of minimal scarring and inflammation.
- Surgical incision healing and strength were significantly improved with the PEAK PlasmaBlade compared with traditional electrosurgical devices.
Other preclinical studies have shown that PEAK Surgical’s proprietary pulsed plasma technology cuts tissue at an average temperature that is half that of standard electrosurgery technology. This lower temperature results in reduced heat transfer and thermal damage to surrounding tissue, preserving healthy tissue. 
Based on these findings, PEAK Surgical believes that the PEAK PlasmaBlade may offer a new alternative for surgeons to potentially provide better outcomes for their patients, including increased procedure efficiency, reduced scarring, faster and stronger wound healing and faster recovery.
Early Clinical Development Results
PEAK Surgical’s pulsed plasma and electrode insulation technologies were initially evaluated in ophthalmology trials, including in human retinal and cataract surgery – one of the most delicate, precise and difficult types of surgery.
Results from a pilot study investigating the use of the PEAK technology for vitreoretinal surgery demonstrated very precise cutting, the ability to make soft tissue cuts without affecting harder tissues such as vascular walls, and limited intraoperative bleeding.
Additional clinical results of PEAK Surgical’s technology have been published in several peer-reviewed journals, including Retina, Archives of Ophthalmology, Journal of Cataract & Refractive Surgery and the British Journal of Ophthalmology.
Clinical Evaluation Strategy
PEAK Surgical is planning to evaluate the PEAK PlasmaBlade in numerous clinical specialties. If you have an interest in participating in these evaluations, please contact our medical director, Grace Carlson, M.D., at gcarlson@peaksurgical.com.
For publications describing the clinical use of PEAK’s technology, click here.
